StockDuty ← Dashboard Aug 07, 2026 08:51 AM ET
SignalFDA/Bio

Cognition Therapeutics Q2 Net Loss Narrows; Plans Phase 3 DLB Study Of Zervimesine In Mid 2027

Narrower Q2 loss and planned Phase 3 DLB study of Zervimesine in mid-2027.

What changed
Why it matters
Narrower Q2 loss and planned Phase 3 DLB study of Zervimesine in mid-2027.
Sources
eodhd
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →